Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 5661 record(s)

Req # A-2024-000017

Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number: 1026516, 1043922. ADRs for HYDROXYCHLOROQUINE. Report numbers: 1024918, 1026702, 1037377.

Organization: Health Canada

70 page(s)
April 2024

Req # A-2024-000028

Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.

Organization: Health Canada

29 page(s)
April 2024

Req # A-2024-000032

Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.

Organization: Health Canada

76 page(s)
April 2024

Req # A-2024-000068

Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.

Organization: Health Canada

3 page(s)
April 2024

Nothing to report this month

Organization: Federal Economic Development Agency for Northern Ontario

April 2024

Req # ATI2024-032

``“[…] We make the following requests for the period January 1, 2004 to November 30, 2023 (the "Period"), unless otherwise indicated: (1) All records related in anyway to Suncor, EDC, and Libya (2) Any communications relating to risks associated with Libya as a financial institution. (3) Any communications between EDC and the Business Development Bank of Canada that relate in any way to EDC's provision of Political Risk Insurance.”

Organization: Business Development Bank of Canada

0 page(s)
March 2024

Req # ATI2024-031

Client File

Organization: Business Development Bank of Canada

184 page(s)
March 2024

Req # A-2023-0004

Briefing note MIN-BN-1019 Electra

Organization: Federal Economic Development Agency for Northern Ontario

3 page(s)
March 2024

Req # A-2016-000420

Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings between Celltrion (health care company) and Health Canada between September 1, 2014 and June 30, 2015.

Organization: Health Canada

299 page(s)
March 2024

Req # A-2019-001464

All domestic Adverse Drug Reaction (ADR) reports for Tetanus, Diphtheria and Pertussis (Tdap) Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Polio Vaccine (IPV), Diphtheria, Tetanus and Pertussis (DTaP), Flu for the period of October 1, 2018 - end of March 2019.

Organization: Health Canada

3917 page(s)
March 2024
Date modified: